Generex Biotechnology Completes Acquisition of Olaregen Therapeutix Inc.
08 janv. 2019 13h29 HE
|
Generex Biotechnology Corp.
- Closes transaction to complete 51% acquisition of Olaregen Therapeutix - Plans Commercial Launch of FDA-cleared Excellagen® MIRAMAR, Fla., Jan. 08, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE --...
Generex Biotechnology Introduces Treatment Alternative to $6 Billion Ulcerative Colitis Surgery Market
07 janv. 2019 15h42 HE
|
Generex Biotechnology Corp.
Announces closing of 51% acquisition of regenerative medicine company Regentys™Regentys Extracellular Matrix Hydrogel for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases ...
GNBT – Generex Biotechnology Plans Breast Cancer Vaccine Spinout and Dividend
04 janv. 2019 11h59 HE
|
Generex Biotechnology Corp.
Generex Biotechnology Provides Update on NuGenerex Immuno-Oncology Update on AE37 Clinical Trial NuGenerex Immuno-Oncology Spin Out and Stock Dividend MIRAMAR, Fla., Jan. 04, 2019 (GLOBE...
UPDATE -- Generex Biotechnology Makes Major Advance On $22 Billion Wound Care Market Announcing Milestone Agreement
03 janv. 2019 17h39 HE
|
Generex Biotechnology Corp.
Generex Biotechnology Partner Olaregen Therapeutix Inc. Signs Manufacturing Agreements for Excellagen® Wound Healing Collagen Matrix Collagen Solutions & Berkshire Sterile Manufacturing to Supply...
Generex Biotechnology Makes Major Advance On $22 Billion Wound Care Market Announcing Milestone Agreement
03 janv. 2019 11h49 HE
|
Generex Biotechnology Corp.
Generex Biotechnology Partner Olaregen Therapeutix Inc. Signs Manufacturing Agreements for Excellagen® Wound Healing Collagen Matrix Collagen Solutions & Berkshire Sterile Manufacturing to Supply...
GNBT - Goldman Small Cap Research Issues Research Report on Generex Biotechnology Corp. and Interview with its CEO
05 nov. 2018 11h30 HE
|
Generex Biotechnology Corp.
BALTIMORE, Nov. 05, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Generex Biotechnology Corp. (GNBT), an emerging, diversified health care provider, announced today that Goldman Small Cap Research, a...
Generex Oncology Announces Consultancy of Dr. George E. Peoples, MD
02 sept. 2010 09h30 HE
|
Generex Biotechnology Corp.
WORCESTER, Mass., Sept. 2, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (Nasdaq:GNBT) today announced the engagement of Dr. George E. Peoples, Jr., M.D., F.A.C.S. as a...
Generex Biotechnology Initiates Social Media Campaign for Its Corporate and e-Commerce Websites
01 sept. 2010 09h30 HE
|
Generex Biotechnology Corp.
WORCESTER, Mass., Sept. 1, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced...
Generex Informs Stockholders of Minimum Exchange Ratio for Reverse Stock Split Proposal to be Considered at the Special Meeting of Stockholders on September 17, 2010
27 août 2010 16h30 HE
|
Generex Biotechnology Corp.
WORCESTER, Mass., Aug. 27, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of...
Generex Oncology Names Dr. Craig Eagle to Its Scientific Advisory Board to Assist With Its Proprietary Cancer Vaccines Program
05 août 2010 09h30 HE
|
Generex Biotechnology Corp.
WORCESTER, Mass., Aug. 5, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com/">www.generex.com) announced today that it has named Craig Eagle, M.D. to its...